Ticker brief
MAZE
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
8
authors 14d
4
crowd 14d
+0.22
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-10-07 → 2026-10-16 · now +0.35 (−1 bearish … +1 bullish)
Who spoke4
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @BiopharmIQ | B | · | 4 | +0.00 |
| @OzmosiHealth | C | · | 2 | +0.00 |
| @PolycarpFX | B | +0.16 | 1 | +0.10 |
| @semodough | C | -1.06 | 1 | +0.35 |
Recent signals8of 8 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-16 | @semodough | +0.35 | A Cantor survey ranks favorite and least-favorite SMID-cap biotech stocks. | · | tweet ↗ |
| 2026-10-13 | @PolycarpFX | +0.10 | Corn emoji suggests mild enthusiasm, but the media is required for context. | · | tweet ↗ |
| 2026-10-11 | @BiopharmIQ | +0.00 | Flags MAZE's October 24 Phase 2 presentation as a potential stock-moving catalyst. | · | tweet ↗ |
| 2026-10-11 | @BiopharmIQ | +0.00 | Reports relative hedge-fund holder counts for three biotech catalyst names. | · | tweet ↗ |
| 2026-10-11 | @BiopharmIQ | +0.00 | Provides a Q4 watchlist of Phase 2 and Phase 3 biotech catalysts. | · | tweet ↗ |
| 2026-10-07 | @OzmosiHealth | +0.00 | Schedules Phase 2 MZE-829 kidney-disease results for 2026-10-24. | · | tweet ↗ |
| 2026-10-07 | @OzmosiHealth | +0.00 | Schedules Phase 0 MZE-782 results for 2026-10-23. | · | tweet ↗ |
| 2026-10-07 | @BiopharmIQ | +0.00 | Summarizes midday biotech news and associated stock moves for a broad list. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.